Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2015048543) TREATING DISORDERS ASSOCIATED WITH ABERRANT ADRENOCORTICAL CELL BEHAVIOR
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2015/048543 International Application No.: PCT/US2014/057854
Publication Date: 02.04.2015 International Filing Date: 26.09.2014
IPC:
A61K 31/343 (2006.01) ,A61K 31/5375 (2006.01) ,A61P 35/00 (2006.01) ,A61P 5/38 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
34
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
343
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5
Drugs for disorders of the endocrine system
38
of the suprarenal hormones
Applicants:
MILLENDO THERAPEUTICS, INC. [US/US]; 301 N. Main Street, Suite 100 Ann Arbor, Michigan 48104, US
THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; US
Inventors:
HUNT, Stephen, Warren, III; US
OWENS, Julia, Christine; US
RAINEY, William, E., II; US
LAPENSEE, Christopher, R.; US
HAMMER, Gary, D.; US
Agent:
HERMANNS, Karl, R.; US
Priority Data:
61/883,08926.09.2013US
62/015,18720.06.2014US
Title (EN) TREATING DISORDERS ASSOCIATED WITH ABERRANT ADRENOCORTICAL CELL BEHAVIOR
(FR) TRAITEMENT DE TROUBLES ASSOCIÉS À UN COMPORTEMENT ABERRANT DES CELLULES ADRÉNOCORTICALES
Abstract:
(EN) Methods and agents are provided for treatment of disorders associated with aberrant adrenocortical cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC) and/or Cushing's syndrome. Such methods involve administration of an agent which exhibits an IC50 value against huACAT1 of less than 10 µM, and one or more further characteristics including effects on adrenocortical cells, disruption of cholesterol homeostasis, reduction in steroid biosynthesis, reduction of mitochondrial function, and/or preferential binding to by low-density lipoprotein (LDL).
(FR) L'invention concerne des méthodes et des agents pour le traitement de troubles associés à un comportement aberrant des cellules adrénocorticales, y compris (mais sans caractère limitatif) le traitement d'un carcinome adrénocortical (ACC) et/ou du syndrome de Cushing. De telles méthodes impliquent l'administration d'un agent qui présente une valeur CI50 vis-à-vis de huACAT1 inférieure à 10 µM et une ou plusieurs caractéristiques supplémentaires comprenant des effets sur des cellules adrénocorticales, une perturbation de l'homéostasie du cholestérol, une réduction de la biosynthèse de stéroïdes, une réduction de la fonction mitochondrique et/ou une liaison préférentielle par une lipoprotéine à basse densité (LDL).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)